Literature DB >> 34991886

LRRK2 and idiopathic Parkinson's disease.

Emily M Rocha1, Matthew T Keeney2, Roberto Di Maio1, Briana R De Miranda3, J Timothy Greenamyre4.   

Abstract

The etiology of idiopathic Parkinson's disease (iPD) is multifactorial, and both genetics and environmental exposures are risk factors. While mutations in leucine-rich repeat kinase-2 (LRRK2) that are associated with increased kinase activity are the most common cause of autosomal dominant PD, the role of LRRK2 in iPD, independent of mutations, remains uncertain. In this review, we discuss how the architecture of LRRK2 influences kinase activation and how enhanced LRRK2 substrate phosphorylation might contribute to pathogenesis. We describe how oxidative stress and endolysosomal dysfunction, both of which occur in iPD, can activate non-mutated LRRK2 to a similar degree as pathogenic mutations. Similarly, environmental toxicants that are linked epidemiologically to iPD risk can also activate LRRK2. In aggregate, current evidence suggests an important role for LRRK2 in iPD.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  autophagy–lysosomal pathway; endogenous protein expression; environmental toxicants; kinase; oxidative stress

Mesh:

Substances:

Year:  2022        PMID: 34991886      PMCID: PMC8854345          DOI: 10.1016/j.tins.2021.12.002

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  101 in total

1.  Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells.

Authors:  Kirsi Ketola; Paula Vainio; Vidal Fey; Olli Kallioniemi; Kristiina Iljin
Journal:  Mol Cancer Ther       Date:  2010-12       Impact factor: 6.261

2.  Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.

Authors:  Miguel Mendivil-Perez; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio
Journal:  Neurochem Res       Date:  2016-07-09       Impact factor: 3.996

3.  Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3.

Authors:  Kathrin Muda; Daniela Bertinetti; Frank Gesellchen; Jennifer Sarah Hermann; Felix von Zweydorf; Arie Geerlof; Anette Jacob; Marius Ueffing; Christian Johannes Gloeckner; Friedrich W Herberg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-18       Impact factor: 11.205

4.  PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats.

Authors:  Michael Aagaard Andersen; Karen Malene Wegener; Steen Larsen; Lassina Badolo; Garrick Paul Smith; Ross Jeggo; Poul Henning Jensen; Florence Sotty; Kenneth Vielsted Christensen; Annemette Thougaard
Journal:  Toxicology       Date:  2018-01-04       Impact factor: 4.221

5.  Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.

Authors:  João P L Daher; Hisham A Abdelmotilib; Xianzhen Hu; Laura A Volpicelli-Daley; Mark S Moehle; Kyle B Fraser; Elie Needle; Yi Chen; Stefanus J Steyn; Paul Galatsis; Warren D Hirst; Andrew B West
Journal:  J Biol Chem       Date:  2015-06-15       Impact factor: 5.157

6.  LRRK2 levels in immune cells are increased in Parkinson's disease.

Authors:  D A Cook; G T Kannarkat; A F Cintron; Laura M Butkovich; Kyle B Fraser; J Chang; N Grigoryan; S A Factor; Andrew B West; J M Boss; M G Tansey
Journal:  NPJ Parkinsons Dis       Date:  2017-03-28

7.  The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain.

Authors:  Sven H Schmidt; Matthias J Knape; Daniela Boassa; Natascha Mumdey; Alexandr P Kornev; Mark H Ellisman; Susan S Taylor; Friedrich W Herberg
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-10       Impact factor: 11.205

8.  Distinct Roles for RAB10 and RAB29 in Pathogenic LRRK2-Mediated Endolysosomal Trafficking Alterations.

Authors:  Pilar Rivero-Ríos; Maria Romo-Lozano; Belén Fernández; Elena Fdez; Sabine Hilfiker
Journal:  Cells       Date:  2020-07-17       Impact factor: 6.600

9.  Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease.

Authors:  Mike A Nalls; Ziv Gan-Or; Hampton Leonard; Cornelis Blauwendraat; Lynne Krohn; Faraz Faghri; Hirotaka Iwaki; Glen Ferguson; Aaron G Day-Williams; David J Stone; Andrew B Singleton
Journal:  J Med Genet       Date:  2019-11-29       Impact factor: 6.318

10.  PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins.

Authors:  Kerryn Berndsen; Pawel Lis; Wondwossen M Yeshaw; Paulina S Wawro; Raja S Nirujogi; Melanie Wightman; Thomas Macartney; Mark Dorward; Axel Knebel; Francesca Tonelli; Suzanne R Pfeffer; Dario R Alessi
Journal:  Elife       Date:  2019-10-30       Impact factor: 8.140

View more
  7 in total

1.  Novel N-Linked Isoquinoline Amides as LRRK2 Inhibitors for Treating Parkinson's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-06-21       Impact factor: 4.632

2.  2-Aminoquinazolines as LRRK2 Inhibitors for Treating Parkinson's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-04-22       Impact factor: 4.632

Review 3.  LRRK2 and Proteostasis in Parkinson's Disease.

Authors:  María Dolores Pérez-Carrión; Inmaculada Posadas; Javier Solera; Valentín Ceña
Journal:  Int J Mol Sci       Date:  2022-06-18       Impact factor: 6.208

4.  NADPH oxidase 2 activity in Parkinson's disease.

Authors:  Matthew T Keeney; Eric K Hoffman; Kyle Farmer; Christopher R Bodle; Marco Fazzari; Alevtina Zharikov; Sandra L Castro; Xiaoping Hu; Amanda Mortimer; Julia K Kofler; Eugenia Cifuentes-Pagano; Patrick J Pagano; Edward A Burton; Teresa G Hastings; J Timothy Greenamyre; Roberto Di Maio
Journal:  Neurobiol Dis       Date:  2022-05-13       Impact factor: 7.046

Review 5.  The Double-Faceted Role of Leucine-Rich Repeat Kinase 2 in the Immunopathogenesis of Parkinson's Disease.

Authors:  Mengfei Zhang; Chaoyi Li; Jie Ren; Huakun Wang; Fang Yi; Junjiao Wu; Yu Tang
Journal:  Front Aging Neurosci       Date:  2022-05-11       Impact factor: 5.702

Review 6.  Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.

Authors:  Gunjan Thakur; Vikas Kumar; Keun Woo Lee; Chungkil Won
Journal:  Genes (Basel)       Date:  2022-08-11       Impact factor: 4.141

7.  High-content phenotyping of Parkinson's disease patient stem cell-derived midbrain dopaminergic neurons using machine learning classification.

Authors:  Aurore Vuidel; Loïc Cousin; Beatrice Weykopf; Simone Haupt; Zahra Hanifehlou; Nicolas Wiest-Daesslé; Michaela Segschneider; Joohyun Lee; Yong-Jun Kwon; Michael Peitz; Arnaud Ogier; Laurent Brino; Oliver Brüstle; Peter Sommer; Johannes H Wilbertz
Journal:  Stem Cell Reports       Date:  2022-09-29       Impact factor: 7.294

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.